Blocking iron uptake and metabolism has been emerging as a promising therapeutic strategy for the development of novel antimicrobial compounds. Like all mycobacteria, M. abscessus (Mab) has evolved several countermeasures to scavenge iron from host carrier proteins, including the production of siderophores, which play a crucial role in these processes. In this study, we solved, for the first time, the crystal structure of Mab-SaS, the first enzyme involved in the biosynthesis of siderophores. Moreover, we screened a small, focused library and identified a compound exhibiting a potent inhibitory effect against Mab-SaS (IC50 ≈ 2 μM). Its binding mode was investigated by means of Induced Fit Docking simulations, performed on the crystal structure presented herein. Furthermore, cytotoxicity data and pharmacokinetic predictions revealed the safety and drug-likeness of this class of compounds. Finally, the crystallographic data were used to optimize the model for future virtual screening campaigns. Taken together, the findings of our study pave the way for the identification of potent Mab-SaS inhibitors, based on both established and unexplored chemotypes.
Structural basis for specific inhibition of salicylate synthase from Mycobacterium abscessus / M. Mori, M. Cocorullo, A. Tresoldi, G. Cazzaniga, A. Gelain, G. Stelitano, L.R. Chiarelli, M. Tomaiuolo, P. Delre, G.F. Mangiatordi, M. Garofalo, A. Cassetta, S. Covaceuszach, S. Villa, F. Meneghetti. - In: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. - ISSN 0223-5234. - 265:(2024 Feb 05), pp. 116073.1-116073.13. [10.1016/j.ejmech.2023.116073]
Structural basis for specific inhibition of salicylate synthase from Mycobacterium abscessus
M. MoriPrimo
;A. Tresoldi;G. Cazzaniga;A. Gelain;S. Villa
Penultimo
;F. MeneghettiUltimo
2024
Abstract
Blocking iron uptake and metabolism has been emerging as a promising therapeutic strategy for the development of novel antimicrobial compounds. Like all mycobacteria, M. abscessus (Mab) has evolved several countermeasures to scavenge iron from host carrier proteins, including the production of siderophores, which play a crucial role in these processes. In this study, we solved, for the first time, the crystal structure of Mab-SaS, the first enzyme involved in the biosynthesis of siderophores. Moreover, we screened a small, focused library and identified a compound exhibiting a potent inhibitory effect against Mab-SaS (IC50 ≈ 2 μM). Its binding mode was investigated by means of Induced Fit Docking simulations, performed on the crystal structure presented herein. Furthermore, cytotoxicity data and pharmacokinetic predictions revealed the safety and drug-likeness of this class of compounds. Finally, the crystallographic data were used to optimize the model for future virtual screening campaigns. Taken together, the findings of our study pave the way for the identification of potent Mab-SaS inhibitors, based on both established and unexplored chemotypes.File | Dimensione | Formato | |
---|---|---|---|
EJMC 2024 Villa et al..pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
5.28 MB
Formato
Adobe PDF
|
5.28 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.